In 2008, Adenosine was acquired by Clinical Data and, due to various subsequent transactions is now (2019) a division of Allergan PLC. With strong ties originally to the University of Virginia (UVa) in Charlottesville. ATL Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that selectively target the four known adenosine receptor subtypes. Candidates for drug development are identified and screened using the companyâs state-of-the-art adenosine receptor screening platform technology. The company was founded with the goal of taking new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include inflammatory indications, sepsis, heart attack, ischemia-reperfusion injury, vascular injury, spinal cord injury, COPD, asthma, diabetes, obesity, inflammatory bowel disease, retinopathy, and Parkinsonâs disease. The companyâs most advanced drug development program is in Phase III clinical develop
